Lund, Sweden, May 25, 2026. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today announced that results from its US Phase 3 ConfIdeS trial in kidney transplantation have been accepted and selected as a late-breaking abstract for an oral presentation at the upcoming American Transplant Congress (ATC) in Boston, June 22, 2026. Read more…
FDA feedback supports Poolbeg’s proposed development pathway for POLB 001, providing further clarity for ongoing partnering discussions 26 May 2026- Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces the positive outcome of a pre-Investigational New Drug (IND) meeting with the U.S. Food and Drug […]
Results support progression of EMERALD clinical trial of Resolution’s engineered macrophage therapy, RTX001 Four-year follow-up data from the University of Edinburgh’s MATCH study, led by Resolution Therapeutics’ founder Professor Stuart Forbes, published in the journal Cell Stem Cell Resolution is pioneering engineered Regenerative Macrophage Therapy – which uses engineered macrophages designed to deliver a more […]
Subset analysis shows early clinical activity supported by biomarker evidence of targeting cancer stem cell pathways driving tumor growth and progression 22 May 2026, Cambridge, UK: STORM Therapeutics Ltd. (STORM), the clinical stage company targeting RNA modifications to reprogram cells and develop novel cancer therapies, today announces that a subset analysis of sarcoma patients enrolled […]
— STARLYS trial to evaluate the potential of MST-0312, a targeted lymphotoxin-beta (LTBR) agonist bispecific antibody, as a novel therapeutic strategy for the treatment of solid tumors. — Study to evaluate tertiary lymphoid structure (TLS) and high endothelial venule (HEV) formation in the tumor as well as clinical responses, as monotherapy and in combination with […]
